Canada Markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.15-0.23 (-2.22%)
At close: 4:00PM EST

10.15 0.00 (0.00%)
After hours: 7:55PM EST

Full screen
Trade prices are not sourced from all markets
Previous Close10.38
Bid10.15 x 800
Ask10.25 x 2200
Day's Range9.74 - 10.39
52 Week Range2.28 - 33.79
Avg. Volume16,092,032
Market Cap1.72B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.32
Earnings DateNov. 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.71
  • 3 Long-Shot Coronavirus Vaccine Stocks to Watch in December
    Motley Fool

    3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

    Now that Moderna and Pfizer have both announced that their coronavirus vaccine candidates appear to be effective at preventing infection, distant laggards look less desirable than ever. Inovio Pharmaceuticals (NASDAQ: INO), Vaxart (NASDAQ: VXRT), and Novavax (NASDAQ: NVAX) aren't going to start selling their candidates to the public anytime soon, but they could still be lucrative stocks. All three have moved more slowly than Moderna and Pfizer, but they share one of the same challenges.

  • Why Inovio Stock Slid Today
    Motley Fool

    Why Inovio Stock Slid Today

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sliding 5.2% lower as of 3:45 p.m. EST on Friday. The company announced earlier in the day that positive results from a phase 2 study evaluating INO-5401 and INO-9012 in combination with cancer immunotherapy Libtayo will be presented at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting. In addition, investors appear to be much more heavily focused on Inovio's COVID-19 program than anything else right now.

  • Is Inovio Back in the Coronavirus Vaccine Race?
    Motley Fool

    Is Inovio Back in the Coronavirus Vaccine Race?

    The FDA has lifted a clinical hold on the biotech's phase 2 study, boosting its prospects for the future.